Prasad S Adusumilli, ELCS 2022: Potential of CAR-T Therapy in Lung Cancer
There is still extensive ongoing research, however CAR-T technology for lung cancer is providing much promise but many challenges. touchONCOLOGY spoke to Dr Prasad S Adusumilli (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) to discuss the potential of CAR-T therapy in lung cancer and the recent breakthroughs in this area.
- What are the barriers to the use of CAR-T therapies in solid tumours, and how can these be overcome? 00:24-01:46
- Could you tell us a little about the findings from your research on CAR T-cell therapy for mesothelioma? 01:46-03:24
- What is the rationale for using immune checkpoint inhibitors in combination with CAR T-cell therapy? 03:24-04:35
- What will be the next steps in your research? 04:35-05:34
- What other molecular targets are currently under evaluation for CAR T-cell therapy for lung cancer? 05:34-
Speaker Disclosure: Prasad S Adusumilli is a consultant for: Atara Biotherapeutics, Bayer, Johnson&Johnson and Orion Pharma. He has received grant and research support from: Atara Biotherapeutics, Baker Street Foundation, Batishwa Fellowship, Comedy vs Cancer Award, DallePezze Foundation, Derfner Foundation, Esophageal Education Research Foundation (ECEF), DOD (BC132124, LC160212, CA170630, CA180889, CA200437), Experimental Therapeutics Center (MSK), Geoffrey Beene Foundation (MSK), NCI (R01 CA236615-01, R01 CA 235667-01A1, R01 CA217169-01A1, R21 CA213139, T32, P30 CA008748) and Technology Development Fund (MSK). He is a member of the advisory board for: BioArdis, Carisma Therapeutics, Bayer, Imugene and ImmPACT Bio. He is a major stock shareholder in: ImmPACT Bio. Other Financial or Material Support: Licensing and Royalty from Mesothelin CAR and PD1 DNR licensed to Atara Biotherapeutics; Patents (issued and applications): Mesothelin CAR, PD1DNR, CARs with new targets and costimulatory domain, Ex-vivo pleural effusion culture system (ePECS), Wireless pulse oximetry (Wipox) device and detection of cancer cells by oncolytic virus.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Summit 2022
Share this Video
Related Videos In Lung Cancer
Sunil Singhal, AACR 2023: Intraoperative molecular imaging as a tool in cancer surgery
Intraoperative molecular imaging enables surgeons to utilise a cancer specific fluorescent dye to improve cancer removal. In this touchONCOLOGY interview, we speak with Dr Sunil Singhal (University of Pennsylvania, Philadelphia, PA, USA) to discuss intraoperative molecular imaging, with focus on its application in lung cancer. The presentation entitled ‘Intraoperative molecular imaging of lung cancer: The […]
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!